STEM-MYO Program | Immunis, Inc.
Service description
A Phase 1/2a clinical trial testing the safety, tolerability, and preliminary efficacy of IMM01-STEM in elderly individuals with age-related muscle atrophy associated with knee osteoarthritis.
Immunis, Inc.
Irvine, United States (US)
Price:
N/A
Quote request
Message
